Page 3 - Scientific Library

Tumour immune evasion can be mediated by a complex set of interaction involving p53, miR-34 and PDL1. This is the conclusion of a work by Cortez et al. and recently published in JCNI .

The

The Blood-Brain Barrier (BBB) affects the development of drugs for all pathologies (brain exposure to drugs, side effects...). In the early phases of drug development, there is a strong need for stable

Messenger RNAs - a promising class of new therapeutic biologics

As messenger RNAs (mRNAs) are easier to deliver into cells than plasmids or viral vectors, they are useful for non-dividing cells.

Following the start of our recent collaboration with Phenocell, we’re pleased to be able to provide high quality Sebocytes developed from Human

In the last few decades, in the field of Drug Discovery, Immunotherapy has gained more and more importance for the treatment of various diseases and in particular for certain types of

PD-1:PD:-L1 immune checkpoint pathway targeting immunotherapies have shown great potential for many cancer patients. Recently, The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab

Gene reporter assays are widely used in research and Drug Discovery. The development of such cell lines is often time-consuming and costly, sometimes upwards of 5-20k € per cell line.

As discussed previously in our recent Drug Discovery post, Immunotherapy is one of the central research fields for various disease treatments and also certain cancers. A major regulator

Recently, BPS Bioscience have released a new Adenosine A2A Receptor (A2AR / ADORA2A) Functional Recombinant Cell Line for screening A2AR agonists and antagonists. An excellent means to

Since the discovery of reprogramming factors in 2006 and the boom of CRISPR gene editing strategies, induced pluripotent stem cells (iPSC) have emerged as new cellular models. The development

Developing new therapeutic agents to boost the immune system and avoid the escape of diseased cells from the natural defenses is the common goal of all researchers in Immunotherapy. To greatly reduce time

In a previous post, we introduced our Ready-to-use cellular models for SLC assays by GenoMembrane.

These cell lines transiently express the current FDA and EMA recommended SLC